We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Toolkit for Reductive Amination in Drug Discovery

By Biotechdaily staff writers
Posted on 23 Jun 2003
A toolkit is designed to simplify the incorporation of reductive amination in chemical drug discovery.

Conventional product workup and purification for reductive amination can be time-consuming and inefficient. In contrast, the resin-bound reagents and scavengers in the toolkit deliver high-purity products requiring only a simple filtration step for product purification. The format allows rapid comparison of pre-defined protocols to determine the best procedure for specific target compounds.

The resin-bound reductants in the toolkit include MP-triacetoxyborohydride and MP-cyanoborohydride. The toolkit is the product of Argonaut Technologies, Inc. (Foster City, CA, USA; www.argotech.com). The company notes that according to The Comprehensive Medicinal Drug Database, about 75% of all chemical drugs currently in development could utilize this reaction.

"Drug discovery and medicinal chemists need simpler access to the chemical compounds generated using this reaction class,” said Howard D. Goldstein, senior vice president of Argonaut Technologies. "Reductive amination is a powerful tool that's used routinely to generate structurally diverse drug candidates.”




Related Links:
Argonaut

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Latest BioResearch News

New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
23 Jun 2003  |   BioResearch

Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
23 Jun 2003  |   BioResearch

Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
23 Jun 2003  |   BioResearch



ADLM